講師
Wei-Kuang Chi
Session 6 – Protein Drugs and Combination Products
Date: 25 July (Thursday) 14:00 – 17:30
Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom B
 |
Wei-Kuang Chi Vice President, R&D |
Dr. Wei-Kuang Chi, Vice President Since November 20, 2019 of the Development Center for Biotechnology (DCB), obtained his M.S in Engineering and Ph.D. in Chemical Engineering from the University of Pennsylvania, Philadelphia, USA. Dr. Chi has over 30 years of experience in biotechnology process development. He established DCB’s multi-product 500 L mammalian cell culture and 100 L microbial fermentation CGMP Biopharmaceutical Pilot Plant Facility (BPPF) and certified by Taiwan Department of Health (DOH) on December 2005 and received DMF with USA FDA on March 2006. The CGMP BPPF has been spun-off on 2013 into private sector to provide CDMO service on a broader scale. Dr. Chi’s new responsibility will focus on new drug R&D, international collaboration, novel bioengineering technology, CAR-T/iPSC development, application of deep learning/AI on drug discovery and /biomanufacturing process
Session Speech Title & Synopsis:
Advanced Platform Technologies for Biotherapeutics Development
DCB is a non-for-profit R&D institute established on 1984, we have established platform technologies for Biotherapeutics developments:
- Autoimmune disease phage library for antibody screening
- Site-specific and possible dual-payload antibody-drug conjugate platform
- High yield CHO-C cell line development and up to 50 L process scale-up
- Integrated continuous bioprocess enabling 2 g/L/day throughput coupled with continuous purificationEfficient CAR-T process under serum free condition with over 100 cell expansion fold within a week with quality
- Autoimmune disease phage library for antibody screening
- Site-specific and possible dual-payload antibody-drug conjugate platform
- High yield CHO-C cell line development and up to 50 L process scale-up
- Integrated continuous bioprocess enabling 2 g/L/day throughput coupled with continuous purificationEfficient CAR-T process under serum free condition with over 100 cell expansion fold within a week with quality